An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026.
from Medical Xpress - latest medical and health news stories https://ift.tt/4W3Pynx
